Skip to main content
. 2022 Oct 28;14(21):5309. doi: 10.3390/cancers14215309

Table 4.

Specific information of three candidate apaQTLs in the screening and validation phase.

Histology Type SNPs Phase Genotypes Cases, N (100%) Controls, N (100%) Adjusted OR (95% CI) a p a
LUAD rs10138506 Screening AA 3048 (88.27) 3324 (89.60) 1 (ref) --
CHURC1 AG 390 (11.30) 380 (10.24) 1.12 (0.97–1.30) 0.133
GG 15 (0.43) 6 (0.16) 2.72 (1.05–7.02) 0.038
Dominant model 2.69 (1.04–6.94) 0.041
Recessive model 1.14 (0.99–1.32) 0.071
Additive model 1.16 (1.01–1.33) 0.034
Validation AA 489 (84.90) 591 (89.01) 1 (ref) --
AG 86 (14.93) 72 (10.84) 1.45 (1.03–2.03) 0.033
GG 1 (0.17) 1 (0.15) 1.06 (0.07–17.00) 0.969
Dominant model 1.44 (1.03–2.02) 0.034
Additive model 1.42 (1.02–1.98) 0.038
LUSC rs1130698 Screening TT 493 (75.38) 2915 (78.57) 1 (ref) --
CD151 TC 149 (22.78) 742 (20.00) 1.19 (0.98–1.44) 0.087
CC 12 (1.84) 53 (1.43) 1.39 (0.75–2.56) 0.295
Dominant model 1.34 (0.73–2.46) 0.351
Recessive model 1.20 (0.99–1.45) 0.060
Additive model 1.19 (1.00–1.41) 0.049
Validation TT 153 (75.37) 535 (80.21) 1 (ref) --
TC 47 (23.15) 126 (18.89) 1.36 (0.91–2.02) 0.138
CC 3 (1.48) 6 (0.90) 1.46 (0.33–6.48) 0.615
Dominant model 1.36 (0.92–2.02) 0.125
Additive model 1.32 (0.92–1.90) 0.130
LUSC rs1130719 Screening AA 455 (69.57) 2751 (74.15) 1 (ref) --
CD151 AT 175 (26.76) 882 (23.77) 1.20 (1.00–1.45) 0.052
TT 24 (3.67) 77 (2.08) 1.86 (1.18–2.95) 0.008
Dominant model 1.78 (1.13–2.81) 0.014
Recessive model 1.25 (1.05–1.50) 0.012
Additive model 1.26 (1.08–1.48) 0.002
Validation AA 147 (72.41) 482 (73.59) 1 (ref) --
AT 49 (24.14) 154 (23.51) 1.17 (0.79–1.73) 0.428
TT 7 (3.45) 19 (2.90) 1.28 (0.50–3.26) 0.611
Dominant model 1.18 (0.81–1.72) 0.378
Additive model 1.15 (0.84–1.58) 0.372

a Logistic regression analysis adjusted for age, gender and smoking status.